Skip to main
LGND

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals is a biopharmaceutical company that specializes in drug discovery, early-stage development, and partnerships. With 15 major commercial royalty streams and over 200 active programs, the company has a diverse set of assets in its portfolio. Additionally, its strong free cash flow allows for future royalty acquisitions without relying on external funding. However, there are risks to consider, such as potential declines in key royalty contributors and challenges in integrating acquired companies. Overall, the company's unique market positioning and varied investment approaches make it well-positioned to generate long-term value for shareholders.

Bears say

Ligand Pharmaceuticals is a biopharmaceutical company that relies heavily on partnerships and royalties for revenue. However, the company's recent financial reports have shown declining earnings and lower-than-expected revenues. Additionally, there are concerns about the company's governance standards following its CEO's involvement with a partnership agreement. The success of the company's future hinges on its ability to retain key individuals and make successful capital deployment decisions.

Ligand Pharmaceuticals (LGND) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Ligand Pharmaceuticals (LGND) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $335.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $335.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.